DK151273B - PROCEDURE FOR THE PREPARATION OF THE CHOLESTEROL BIOSYNTHESE INHIBITOR MB-530A. - Google Patents

PROCEDURE FOR THE PREPARATION OF THE CHOLESTEROL BIOSYNTHESE INHIBITOR MB-530A. Download PDF

Info

Publication number
DK151273B
DK151273B DK145481AA DK145481A DK151273B DK 151273 B DK151273 B DK 151273B DK 145481A A DK145481A A DK 145481AA DK 145481 A DK145481 A DK 145481A DK 151273 B DK151273 B DK 151273B
Authority
DK
Denmark
Prior art keywords
compound
cholesterol
culture medium
preparation
microorganism
Prior art date
Application number
DK145481AA
Other languages
Danish (da)
Other versions
DK145481A (en
DK151273C (en
Inventor
Aiya Sato
Akira Terahara
Yoshio Tsujita
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12604367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK151273(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of DK145481A publication Critical patent/DK145481A/en
Priority to DK542085A priority Critical patent/DK159439C/en
Publication of DK151273B publication Critical patent/DK151273B/en
Application granted granted Critical
Publication of DK151273C publication Critical patent/DK151273C/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02Oxygen as only ring hetero atoms
    • C12P17/06Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Description

i 151273in 151273

Den foreliggende opfindelse angår en fremgangsmåde til fremstilling af forbindelsen betegnet MB-530A med inhiberende virkning overfor biosyntesen af cholesterol. MB-530A har formlen (V): 5 0 (V) 10 L i ch3^," ' Y ">xThe present invention relates to a process for the preparation of the compound termed MB-530A with inhibitory effect on the biosynthesis of cholesterol. MB-530A has the formula (V): 50 (V) 10 L in ch 3

O ^ JO ^ J

15 Hyperlipidæmi, især hypercholesterolæmi, vides at være en af hovedårsagerne til cardiopati, såsom hjerteinfarkt eller arteriesclerose. Som resultat heraf har en betydelig forskning været udført med henblik på at finde frem til forbindelser, der er i stand til at formindske lipidmængden, og især chole- 2Q sterolmængden i blodet. En gruppe forbindelser af denne type er omhandlet i USA-patentskrift nr. 3.983.140, hvilke forbindelser isoleres fra mikroorganismer af slægten PeniciIlium.Hyperlipidemia, especially hypercholesterolemia, is known to be one of the major causes of cardiopathy, such as heart attack or arterial sclerosis. As a result, considerable research has been carried out to find compounds capable of reducing the amount of lipid, and especially the cholesterol 2Q sterol in the blood. A group of compounds of this type is disclosed in U.S. Patent No. 3,983,140, which compounds are isolated from microorganisms of the genus Penicillium.

Denne gruppe forbindelser betegnes kollektivt ML-236.This group of compounds is collectively referred to as ML-236.

25 ML-236A og NL-236B (to af forbindelserne i ML-236-komplekset, som er omhandlet i USA-patentskrift nr. 3.983.140) har henholdsvis formlen (II) og (III):25 ML-236A and NL-236B (two of the compounds of the ML-236 complex disclosed in U.S. Patent No. 3,983,140) have formulas (II) and (III), respectively:

so to'rV ΗΟγ Yso to'rV ΗΟγ Y

γ Yγ Y

x \x \

OH 1 9 TOH 1 9 T

CH, I I (ID CH I i (III)CH, I I (ID CH I i (III)

35 YyS Y yS35 YyS Y yS

XXX X XXXXX X XX

151273 2151273 2

Det har nu vist sig, at forbindelsen MB-530A kan fremstilles ved dyrkning af en stamme af arten Monascus ruber, og fremgangsmåden ifølge opfindelsen er i overensstemmelse hermed ejendommelig ved, at man dyrker en stamme af arten Monascus 5 ruber i et dyrkningsmedium derfor, og at den dannede MB-530A-forbindelse fraskilles fra dyrkningsmediet.It has now been found that the compound MB-530A can be prepared by growing a strain of the Monascus rubber species, and the method according to the invention is characterized by cultivating a strain of the Monascus 5 rubber species in a culture medium therefor, and that the MB-530A compound formed is separated from the culture medium.

MB-530A fremstilles fortrinsvis ved dyrkning af stammen Monascus ruber SANK 15177. Denne stamme blev deponeret den 27.MB-530A is preferably produced by cultivating the strain Monascus ruber SANK 15177. This strain was deposited on the 27th.

10 april 1979 under accessionsnummeret FERM 4956 hos The Fermentation Research Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry,April 10, 1979 under the accession number FERM 4956 at The Fermentation Research Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry,

Japan, og den 25. januar 1980 under accessionsnummeret NRRL 12081 hos The Agricultural Research Service Culture Collection, 15 Northern Regional Research Laboratory, Peoria, Illinois, U.S.A.Japan, and on January 25, 1980 under accession number NRRL 12081 at The Agricultural Research Service Culture Collection, 15 Northern Regional Research Laboratory, Peoria, Illinois, U.S.A.

Fra beskrivelsen til den danske patentansøgning nr 731/80, som svarer til fremlæggelsesskrift nr. 148.807, må det anses for kendt at fremstille monacolin K med formlen (IV): 20From the specification to Danish patent application No. 731/80, which corresponds to the present disclosure no. 148.807, it must be considered known to produce monacoline K of formula (IV): 20

HS VHS V

Y o 25 i i ^ 0 CH3\Yv>^k (IV) ^ Ύ' CH-30 3 ved dyrkning af stammer af arten Monacus ruber, bl.a. Monacus 35 ruber SANK 15.177.Y o 25 i i ^ 0 CH3 \ Yv> ^ k (IV) ^ Ύ 'CH-30 3 by cultivating strains of the species Monacus ruber, i.a. Monacus 35 ruber SANK 15.177.

151273 3151273 3

Fra beskrivelsen til den danske patentansøgning nr. 461/81 må det anses for kendt at fremstille bl.a. MB-530A ved en kemisk fremgangsmåde.From the description to the Danish patent application no. 461/81, it must be considered known to produce, inter alia, MB-530A by a chemical process.

5 Forbindelsen MB-530A kan fremstilles ved dyrkning af den udvalgte mikroorganisme i et dyrkningssubstrat under aerobe betingelser under anvendelse af den samme teknik, som er velkendt til dyrkning af svampe og andre mikroorganismer. For eksempel kan den valgte stamme af Monacus ruber først dyrkes IQ på et egnet medium, og den producerede mikroorganisme kan derefter opsamles og podes på og dyrkes på et andet dyrkningsmedium til fremstilling af den ønskede MB-530A-forbindelse.The compound MB-530A can be prepared by culturing the selected microorganism in a culture substrate under aerobic conditions using the same technique well known for growing fungi and other microorganisms. For example, the selected strain of Monacus rubber can first be grown IQ on a suitable medium and the microorganism produced can then be collected and seeded and grown on another culture medium to prepare the desired MB-530A compound.

Det til formeringen af mikroorganismen benyttede dyrkningsmedium og det til produktionen af MB-530A benyttede dyrknings-15 medium kan være ens eller forskellige.The culture medium used for the propagation of the microorganism and the culture medium used for the production of MB-530A may be the same or different.

Ethvert velkendt dyrkningsmedium til dyrkning af svampe kan benyttes, forudsat at det, som der er velkendt, indeholder de nødvendige næringsstoffer, især en assimilerbar carbonkil-20 de og en assimilerbar nitrogenkilde. Eksempler på sådanne kilder for assimilerbart carbon indbefatter glucose, maltose, dextrin, stivelse, lactose, sucrose og glycerol. Af disse kilder er glucose, glycerol og stivelse særlig foretrukne til fremstilling af MB-530A. Eksempler på egnede kilder for 25 assimilerbart nitrogen er pepton, kødekstrakt, gær, gærekstrakt, sojabønnemel, jordnøddemel, majsstøbevæske, risklid og uorganiske nitrogenkilder. Af disse nitrogenkilder er majsstøbevæske og pepton særlig foretrukne. Ved fremstilling af MB-530A kan et uorganisk salt og/eller et metalsalt om nødvendigt 30 sættes til dyrkningsmediet. Endvidere kan om nødvendigt en mindre mængde af et tungt metal også tilsættes.Any well-known culture medium for growing mushrooms can be used provided that, as is well known, it contains the necessary nutrients, in particular an assimilable carbon source and an assimilable nitrogen source. Examples of such sources of assimilable carbon include glucose, maltose, dextrin, starch, lactose, sucrose and glycerol. Of these sources, glucose, glycerol and starch are particularly preferred for the preparation of MB-530A. Examples of suitable sources for assimilable nitrogen are peptone, meat extract, yeast, yeast extract, soybean meal, peanut flour, corn mold liquid, rice bran and inorganic nitrogen sources. Of these nitrogen sources, corn molding liquid and peptone are particularly preferred. In preparing MB-530A, an inorganic salt and / or a metal salt can be added to the culture medium if necessary. Furthermore, if necessary, a smaller amount of a heavy metal can also be added.

Mikroorganismen dyrkes fortrinsvis under aerobe betingelser under anvendelse af dyrkningsmetoder, der er velkendte indenfor 35 teknikken, f.eks. fast dyrkning, rystedyrkning eller dyrkning under luftning og omrøring. Mikroorganismen vil vokse over et bredt temperaturinterval, f.eks. 7 til 40°C, men til 151273 4 fremstilling af MB-530A ligger den mere foretrukne dyrkningstemperatur indenfor intervallet fra 20 til 30°C.The microorganism is preferably grown under aerobic conditions using cultivation methods well known in the art, e.g. solid culture, shaking or aeration and stirring. The microorganism will grow over a wide range of temperatures, e.g. 7 to 40 ° C, but for the preparation of MB-530A, the more preferred culture temperature is within the range of 20 to 30 ° C.

Under dyrkningen af mikroorganismen kan produktionen af MB-530A 5 måles ved prøveudtagning af dyrkningsmedium og måling af mediets fysiologiske aktivitet ved hjælp af velkendte forsøg. Dyrkningen kan derefter fortsættes, indtil en væsentlig akkumulering af MB-530A er blevet opnået i dyrkningsmediet, på hvilket tidspunkt MB-530A-forbindelsen derefter kan isoleres ^0 og udvindes fra dyrkningsmediet ved hjælp af enhver egnet kombination af isolationsteknik, der vælges under hensyntagen til dets fysiske og kemiske egenskaber. For eksempel kan enhver af eller alle de nedenfor anførte isolationsmetoder anvendes: ^5 Ekstraktion af væsken fra dyrkningssubstratet med et hydrofilt opløsningsmiddel (såsom diethylether, ethylacetat, chloroform eller benzen), koncentrering, f.eks. ved afdampning af noget eller en del af opløsningsmidlet under formindsket tryk, opløsning i et mere polært opløsningsmiddel (såsom acetone 2q eller en alkohol), fjernelse af urenheder med et mindre polært opløsningsmiddel (såsom petroleumsether eller hexan), gelfiltrering gennem en søjle af et materiale, såsom "Sephadex" (et handelsnavn for et materiale, der fås fra Pharmacia Co. Limited, U.S.A.), absorptionskromatografi med aktivt carbon 25 eller silicagel og andre lignende metoder. Ved anvendelse .During the cultivation of the microorganism, the production of MB-530A 5 can be measured by sampling culture medium and measuring the physiological activity of the medium by well known experiments. Cultivation can then be continued until a significant accumulation of MB-530A has been obtained in the culture medium, at which time the MB-530A compound can then be isolated and recovered from the culture medium by any suitable combination of isolation technique selected taking into account its physical and chemical properties. For example, any or all of the isolation methods listed below may be used: Extraction of the liquid from the culture substrate with a hydrophilic solvent (such as diethyl ether, ethyl acetate, chloroform or benzene), concentration, e.g. by evaporation of some or all of the solvent under reduced pressure, dissolving in a more polar solvent (such as acetone 2q or an alcohol), removing impurities with a less polar solvent (such as petroleum ether or hexane), gel filtration through a column of a material , such as "Sephadex" (a trade name for a material obtained from Pharmacia Co. Limited, USA), activated carbon 25 or silica gel absorption chromatography, and other similar methods. When used.

af en passende kombination af disse metoder kan den ønskede MB-530A-forbindelse isoleres fra dyrkningssubstratet som et rent stof. 1 2 3 4 5 6by a suitable combination of these methods, the desired MB-530A compound can be isolated from the culture substrate as a pure substance. 1 2 3 4 5 6

Den ifølge opfindelsen fremstillede forbindelse har vist sig 2 at have en specifik inhiberende virkning over for 3-hydroxy-3- 3 methylglutarylcoenzym A reduktase (HMG-CoA reduktase), som 4 er det hastigheds-kontrollerende enzym ved biosyntesen af 5 cholesterol.The compound of the invention has been found to have a specific inhibitory effect against 3-hydroxy-3- 3 methylglutaryl coenzyme A reductase (HMG-CoA reductase), which 4 is the rate-controlling enzyme in the biosynthesis of 5 cholesterol.

66

Fremstillingen af forbindelsen MB-530A illustreres yderligere i det efterfølgende eksempel.The preparation of compound MB-530A is further illustrated in the following example.

151273 5151273 5

EksempelExample

Fremstilling af MB-530APreparation of MB-530A

5 300 1 af et dyrkningsmedium med en pH-værdi på 5,5 før steri lisering og indeholdende 5% vægt/volumen glucose, 0,5% vægt/ volumen maj sstøbevæske og 2% vægt/volumen pepton (Kyokuto fabrikat, fås fra Kyokuto Seiyaku KK, Japan) og 0,5% ammonium-chlorid blev fyldt på en 600 1 gæringsbeholder og podet med 10 en kultur af Monascus ruber SANK 15177 (FERM 4956, NRRL 12081).5,300 l of a culture medium with a pH of 5.5 before sterilization containing 5% w / v glucose, 0.5% w / v maize casting liquid and 2% w / v peptone (Kyokuto make, available from Kyokuto Seiyaku KK, Japan) and 0.5% ammonium chloride were charged to a 600 l fermentation vessel and seeded with a culture of Monascus ruber SANK 15177 (FERM 4956, NRRL 12081).

Dyrkning af microorganismen blev fortsat i 120 timer ved 27°C med en beluftningshastighed på 300 1/min og omrøring med 190 omdrejninger pr. minut.Culture of the microorganism was continued for 120 hours at 27 ° C with an aeration rate of 300 l / min and stirring at 190 rpm. minute.

15 Ved afslutningen af dette tidsrum blev dyrkningssubstratet filtreret i en filterpresse til opnåelse af et filtrat og en filterkage omfattende våde celler af microorganismen.At the end of this time, the culture substrate was filtered into a filter press to obtain a filtrate and a filter cake comprising wet cells of the microorganism.

Filtratet blev indstillet til en pH-værdi på 3,0 ved tilsæt-20 ning af 6N saltsyre og derpå ekstraheret med 400 1 ethylacetat.The filtrate was adjusted to a pH of 3.0 by the addition of 6N hydrochloric acid and then extracted with 400 L of ethyl acetate.

Ekstrakten (ca. 400 1) blev koncentreret ved inddampning under formindsket tryk og derefter afvandet over vandfrit natriumsulfat, hvorefter den blev inddampet til tørhed til opnåelse af ca. 60 g af et olieagtigt produkt. Dette olieagtige pro-25 dukt blev vasket med ethylcyklohexan og med hexan, og resten (20 g), blev separeret ved hjælp af kromatografi under anvendelse af et væskekromatografiapparat til udtagning af prøver med stort volumen (System 500 væskekromatografi, fremstillet afThe extract (about 400 L) was concentrated by evaporation under reduced pressure and then dewatered over anhydrous sodium sulfate, then evaporated to dryness to give ca. 60 g of an oily product. This oily product was washed with ethyl cyclohexane and with hexane, and the residue (20 g) was separated by chromatography using a high volume liquid chromatography apparatus (System 500 liquid chromatography, prepared by

Waters Co., USA), idet der blev elueret . med 60% volumen/vol-30 urnen vandig methanol.Fraktioner med en kromatografisk retentionstid på 6 minutter blev opsamlet og koncentreret ved inddampning under formindsket tryk til opnåelse af 100 mg af den ønskede MB-530A-forbindelse som et olieagtigt produkt. Denne olieagtige MB-530A-forbindelse blev rekrystalliseret fra en blanding af acetone og diethylether til opnåelse af 57 mg af det ønskede produkt i form af farveløse nåle med følgende egenskaber :Waters Co., USA), eluting. with 60% v / v aqueous methanol. Fractions with chromatographic retention time of 6 minutes were collected and concentrated by evaporation under reduced pressure to give 100 mg of the desired MB-530A compound as an oily product. This oily MB-530A compound was recrystallized from a mixture of acetone and diethyl ether to give 57 mg of the desired product in the form of colorless needles having the following properties:

Claims (2)

151273151273 1. Fremgangsmåde til fremstilling af forbindelsen MB-530A med formlen (V):A process for preparing the compound MB-530A of formula (V): 30 HO ^ 0 ^C)30 ° C) 35. OH ch3~C^X^~- (V) 151273 kendetegnet ved, at man dyrker en stamme af arten Monascus ruber i et dyrkningsmedium derfor, og at den dannede MB-530A-forbindelse fraskilles fra dyrkningsmediet.35. OH ch3 ~ C ^ X ^ ~ - (V) 151273 characterized in that a strain of the species Monascus rubs in a culture medium therefor and that the MB-530A compound formed is separated from the culture medium. 1. Smeltepunkt: 92 - 93QC.1. Melting point: 92 - 93 ° C. 2. Grundstofanalyse: Beregnet for ci9H28°4:c 69/76%;H 8,68%. Fundet: C71,22%;H 8,81%.2. Elemental analysis: Calculated for c19 H28 ° 4: c 69/76%; H 8.68%. Found: C71.22%, H 8.81%. 3. Molekylvægt: 320 (ved masseanalyse) .3. Molecular weight: 320 (by mass analysis). 4. Molekylformel: C^9H28°44. Molecular formula: C 28 H 28 ° 4 5. Ultraviolet absorptionsspektrum: Som vist i fig.l på tegningen .5. Ultraviolet absorption spectrum: As shown in Figure 1 of the drawing. 6. Infrarødt absorptions spektrum: Som vist i fig. 2 på tegningen .6. Infrared absorption spectrum: As shown in FIG. 2 of the drawing. 7. Kernemagnetisk resonansspektrum; Som vist i fig. 3 på teg ningen .7. Nuclear Magnetic Resonance Spectrum; As shown in FIG. 3 of the drawing. 8. Opløselighed: Let opløselig i methanol, ethanol, acetone, ethylacetat: Opløselig i benzen: Uopløselig i hexan og petroløumsether.8. Solubility: Easily soluble in methanol, ethanol, acetone, ethyl acetate: Soluble in benzene: Insoluble in hexane and petroleum ether. 9. Farvereaktion: En lyserød farve ses, når et tyndlagskroma-togram af forbindelsen på silikagel fremkaldes med 50% vol-umen/volumen svovlsyre.9. Color reaction: A pink color is seen when a thin layer chromatogram of the compound on silica gel is elicited with 50% volume / volume sulfuric acid. 10. Inhiberende virkning overfor biosyntesen af cholesterol:10. Inhibitory effect on the biosynthesis of cholesterol: 20 En 50% inhibering af cholesterolsyntesen i rottelever iagt tages ved en koncentration på 0,04yg/ml. Patentkrav. 25 ---------------------20 A 50% inhibition of cholesterol synthesis in rat liver is observed at a concentration of 0.04 µg / ml. Claims. 25 --------------------- 2. Fremgangsmåde ifølge krav 1, kendetegnet ved, at mikroorganismen er Monascus ruber SANK 15177 (FERM 4956, NRRL 12081).Method according to claim 1, characterized in that the microorganism is Monascus ruber SANK 15177 (FERM 4956, NRRL 12081).
DK145481A 1980-03-31 1981-03-31 PROCEDURE FOR THE PREPARATION OF THE CHOLESTEROL BIOSYNTHESE INHIBITOR MB-530A. DK151273C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK542085A DK159439C (en) 1980-03-31 1985-11-22 ANALOGY PROCEDURE FOR PREPARING CHOLESTEROL SYNTHESIS INHIBITORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP55041292A JPH0692381B2 (en) 1980-03-31 1980-03-31 MB-530A derivative
JP4129280 1980-03-31

Publications (3)

Publication Number Publication Date
DK145481A DK145481A (en) 1981-10-01
DK151273B true DK151273B (en) 1987-11-16
DK151273C DK151273C (en) 1988-07-04

Family

ID=12604367

Family Applications (3)

Application Number Title Priority Date Filing Date
DK145481A DK151273C (en) 1980-03-31 1981-03-31 PROCEDURE FOR THE PREPARATION OF THE CHOLESTEROL BIOSYNTHESE INHIBITOR MB-530A.
DK032290A DK32290A (en) 1980-03-31 1990-02-07 APPLICATION OF 8'-ACYLED DERIVATIVES OF THE INTERMEDIATE COMPOUND MB-530A FOR THE PREPARATION OF A MEDICINE FOR TREATING HYPERCHOLESTEROLAEMIA
DK032190A DK167805B1 (en) 1980-03-31 1990-02-07 INTERMEDIATE FOR THE PREPARATION OF CHOLESTEROL SYNTHESIS INHIBITORS

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK032290A DK32290A (en) 1980-03-31 1990-02-07 APPLICATION OF 8'-ACYLED DERIVATIVES OF THE INTERMEDIATE COMPOUND MB-530A FOR THE PREPARATION OF A MEDICINE FOR TREATING HYPERCHOLESTEROLAEMIA
DK032190A DK167805B1 (en) 1980-03-31 1990-02-07 INTERMEDIATE FOR THE PREPARATION OF CHOLESTEROL SYNTHESIS INHIBITORS

Country Status (15)

Country Link
JP (1) JPH0692381B2 (en)
AT (1) ATA150781A (en)
AU (1) AU6893281A (en)
BE (1) BE888214A (en)
CH (1) CH646966A5 (en)
DE (2) DE3112566A1 (en)
DK (3) DK151273C (en)
FI (1) FI810991L (en)
FR (1) FR2479222A1 (en)
GB (1) GB2073193A (en)
IE (1) IE52367B1 (en)
IT (1) IT1144325B (en)
MX (1) MX9203567A (en)
NL (1) NL8101592A (en)
SE (1) SE461590B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472426A (en) * 1982-12-22 1984-09-18 Merck & Co., Inc. Antihypercholesterolemic compounds
DE3682557D1 (en) * 1985-09-13 1992-01-02 Sankyo Co HYDROXY-ML-236B DERIVATIVES, THEIR PRODUCTION AND USE.
US4997848A (en) * 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
US5075327A (en) * 1988-08-10 1991-12-24 Hoffmann-La Roche Inc. Antipsoriatic agents
US5073568A (en) * 1988-11-14 1991-12-17 Hoffmann-La Roche Inc. Antipsoriatic agents
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
US5200549A (en) * 1988-11-14 1993-04-06 Hoffman-La Roche Inc. Antipsoriatic agents
US5159104A (en) * 1991-05-01 1992-10-27 Merck & Co., Inc. Process to simvastatin ester
FR2937537A1 (en) 2008-10-29 2010-04-30 Centre Nat Rech Scient NANOPARTICLES OF STATIN
KR101820099B1 (en) 2013-01-18 2018-01-18 에스프린팅솔루션 주식회사 resistive heat generating material, heating member and fusing device adopting the same
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK46181A (en) * 1980-02-04 1981-08-05 Merck & Co Inc PROCEDURE FOR PRODUCING PYRANONES AND INTERMEDIATES FOR USE IN EXERCISING THE PROCEDURE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (en) * 1974-06-07 1981-03-18
JPS5925599B2 (en) * 1979-02-20 1984-06-19 三共株式会社 New physiologically active substance monacolin K and its production method
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
GR69216B (en) * 1979-06-15 1982-05-07 Merck & Co Inc
ZA81703B (en) * 1980-02-04 1982-09-29 Merck & Co Inc New antihypercholesterolemic compounds,intermediates and processes
PT72394B (en) * 1980-02-04 1982-09-06 Merck & Co Inc Process for preparing dihydro and tetrahydromevinoline hypocholesterolimics
US4282155A (en) * 1980-02-04 1981-08-04 Merck & Co., Inc. Antihypercholesterolemic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK46181A (en) * 1980-02-04 1981-08-05 Merck & Co Inc PROCEDURE FOR PRODUCING PYRANONES AND INTERMEDIATES FOR USE IN EXERCISING THE PROCEDURE

Also Published As

Publication number Publication date
DK32290D0 (en) 1990-02-07
DE3112566A1 (en) 1982-03-11
DK145481A (en) 1981-10-01
IE810698L (en) 1981-09-30
CH646966A5 (en) 1984-12-28
IT1144325B (en) 1986-10-29
NL8101592A (en) 1981-10-16
FR2479222A1 (en) 1981-10-02
AU6893281A (en) 1981-10-08
IE52367B1 (en) 1987-09-30
SE8102047L (en) 1981-10-01
FI810991L (en) 1981-10-01
SE461590B (en) 1990-03-05
DE3112566C2 (en) 1990-04-05
GB2073193A (en) 1981-10-14
FR2479222B1 (en) 1983-08-26
JPH0692381B2 (en) 1994-11-16
BE888214A (en) 1981-09-30
JPS56138181A (en) 1981-10-28
DK167805B1 (en) 1993-12-20
DK32190D0 (en) 1990-02-07
IT8167438A0 (en) 1981-03-30
MX9203567A (en) 1992-09-01
DK151273C (en) 1988-07-04
DE3153666C2 (en) 1993-11-11
DK32190A (en) 1990-02-07
DK32290A (en) 1990-02-07
ATA150781A (en) 1983-03-15

Similar Documents

Publication Publication Date Title
DK149095B (en) PROCEDURE FOR PREPARING A CHOLESTEROL SYNTHESIS INHIBITIVE COMPOUND called MONACOLIN K
BG62852B1 (en) Method for lovastatin isolation
DK151273B (en) PROCEDURE FOR THE PREPARATION OF THE CHOLESTEROL BIOSYNTHESE INHIBITOR MB-530A.
CN102965290A (en) Pichia kudriavzevii ZJPH0802 and application thereof in preparation of curcumin derivatives
NZ250344A (en) Zearalenone analogues, their preparation from a fungal fermentation, the fungal strain, and pharmaceutical compositions
JP3854866B2 (en) Method for producing mycophenolic acid and derivatives thereof
EP0356291B1 (en) Process for the microbiological production of gamma-decalactone (R) and gamma-octalactone (R)
EP0043280B1 (en) Process for preparing a macrolide
CN102329829B (en) Method for converting daidzein into 8-hydroxydaidzein by utilizing penicillium
CN106957881B (en) Preparation method of curcumin derivative
JPH0246294A (en) Production of angnocyclinone from streptomyces microorganism and production thereof
US3564019A (en) Tetracyclic lactone antifungal agents
JP2966859B2 (en) Novel bioactive substance dioctatin and method for producing the same
JPH0625277A (en) Bacterium producing novel testosterone-5alpha-reductase-inhibiting substance, sna-4606, novel testosterone-5-reductase-inhibiting substance, sna-4606 and its production
JPH05170769A (en) New compound q-11270 or its production
JP3641013B2 (en) Novel cell adhesion inhibitors Macrospheride A and B and process for producing them
EP0337548A2 (en) HMG-COA reductase inhibitors produced by nocardia SP. (MA6455)(ATCC 53695)
JPH07242636A (en) Fo-3216 substance and its production
EP1080220A1 (en) New biotechnological process for preparing hydroxylated ml-236b derivatives, known as m-4 and m-4', and analogues thereof
JPS5945360B2 (en) Production method of physiologically active substance ML-236B
JPS5840475B2 (en) New physiologically active substance ML-236A and its manufacturing method
EP0629184A1 (en) TETRALIN DERIVATIVES AS HMG-CoA REDUCTASE INHIBITORS
US3634461A (en) Spirostan derivative
JPS6219159B2 (en)
DK165990B (en) Hypocholesterolaemic agent monacolin K - produced by culturing Monascus strain

Legal Events

Date Code Title Description
PTS Application withdrawn
PUP Patent expired